Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.

• Status: Completed
• Trial end date: 2003-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to asses changes in glycosylated hemoglobin, fasting blood lipids and genetic polymorphism's in peroxisomal proliferator activated receptors--gamma receptor after 6 months of pioglitazone, once daily (QD), treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeda
• Collaborator: Eli Lilly and Company
• Treatments: Metformin; Pioglitazone

Criteria

Inclusion Criteria:

• Fulfills all requirements for treatment with pioglitazone.

• Willing to start treatment with pioglitazone.

Exclusion Criteria:

• Has previously participated in this study.

• Is currently taking or have taken oral antidiabetic medications other than sulfonylurea or metformin within the last 30 days.